Netherlands · 
What does EQT life science invest in?
EQT life science invests most often at Series B and Series A (56% of the rounds on record), in sectors such as Medical Devices, Connected Health and In Vitro Diagnostics.
EQT life science highlights
- 01
66 rounds on record
- 02
Mostly Series B and Series A: 56% of its rounds
- 03
17 exits from the portfolio
What they do
- Type
- Private equity (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- Medical DevicesConnected HealthIn Vitro Diagnostics
- Based in
- Amsterdam, Netherlands
- Cold pitches
- Not stated
A website was listed for this organisation, but we could not confirm it belongs to the firm that wrote these cheques. Either the site never mentions them, or it turned out to be a different company sharing the name. We show neither it nor anything read from it. Tell us the right one.
The record
Every round we can evidence, newest first66 appearances
- 2015
3 rounds
- Aug
- Jun
- Mar
- 2014
8 rounds
- Dec
- Nov
- Sept
- Jul
- Jul
- Apr
- Apr
- Apr
- 2013
2 rounds
- Oct
- Oct
- 2012
7 rounds
- Nov
- Oct
- Sept
- Apr
- Jan
- Jan
- Jan
- 2011
8 rounds
- Dec
- Nov
- Jul
- Jun
- Jun
- May
- Feb
- Jan
- 2010
8 rounds
- Nov
- Mar
- Feb
- Feb
- Jan
- Jan
- Jan
- Jan
- 2009
8 rounds
- Dec
- Nov
- Nov
- Nov
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration14 named
APAnne PortwichManager of the ManageriFiling they signed
CSChristiaan SnydersManager of the AIFMiFiling they signed
FAFouad AzzamManager of the ManageriFiling they signed
JRJoachim RotheManager of the AIFMiFiling they signed
LALSP Advisory B.V.AIFMiFiling they signed
MSMagnus SjocronaManager of the AIFMiFiling they signed
MWMark WegterManager of the AIFMiFiling they signed
MKMartijn KleijwegtManager of the AIFMiFiling they signed
MKMerijn KlaassenManager of the AIFMiFiling they signed
PBPatrik BurnasManager of the AIFMiFiling they signed
PVPeter VeldmanManager of the AIFMiFiling they signed
RKRene KuijtenManager of the AIFMiFiling they signed
RDRudy DekeyserManager of the ManageriFiling they signed
SHSara HudaManager of the AIFMiFiling they signed
We also hold 16 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Exits from the portfolio
Companies it backed that were later bought or listed17 in all
Seahorse BioscienceBought by Agilent Technologies$235MSept 2015
Hyperion TherapeuticsBought by Horizon Pharma$1.1BMar 2015
ActoGeniXBought by Intrexon Corporation$60MFeb 2015
ProsensaBought by BioMarin Pharmaceutical$840MNov 2014
SantarusBought by Salix Pharmaceuticals$2.6BNov 2013
Kreatech DiagnosticsBought by Leica Biosystems St. LouisUndisclosedJul 2013
ProsensaListed$78MJun 2013
BMEYEBought by Edwards LifesciencesUndisclosedOct 2012
Pasteuria BioscienceBought by Syngenta$113MSept 2012
FlowCardiaBought by C. R. BardUndisclosedMay 2010
BioProcessorsBought by Seahorse BioscienceUndisclosedMar 2009
NewBioticsBought by Celmed BiosciencesUndisclosedJul 2004
SantarusListedUndisclosedApr 2004
An exit counts when it came after the firm's first round in the company. From historical deal records.